Skip to main content
ERYTECH Pharma S.A. logo

ERYTECH Pharma S.A. — Investor Relations & Filings

Ticker · ERYP ISIN · FR001400K4B1 LEI · 969500U8ZZCODU8A9374 PA Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2023-07-04 Major Shareholding Noti…
Country FR France
Listing PA ERYP

About ERYTECH Pharma S.A.

https://phaxiam.com/

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Recent filings

Filing Released Lang Actions
Franchissements de seuils et déclaration d'intention
Major Shareholding Notification Classification · 1% confidence The document is titled "Déclarations de franchissements de seuils et déclaration d'intention (article L. 233-7 du code de commerce)" and details changes in share ownership thresholds crossed by a concert group in PHAXIAM THERAPEUTICS, along with a declaration of future intentions regarding the company. This content directly corresponds to regulatory filings concerning insider transactions or major shareholding notifications. The French regulatory context (AMF, code de commerce) points towards mandatory disclosure of insider dealings or significant ownership changes. Among the provided codes, 'DIRS' (Director's Dealing) covers personal share transactions by executives, and 'MRQ' (Major Shareholding Notification) covers changes in significant share ownership levels (crossing thresholds). Since the document explicitly details crossing ownership thresholds (15%, 20%, 25%) and provides a detailed breakdown of holdings, it is a Major Shareholding Notification. In the context of French regulations, these are often filed under Article L. 233-7, which mandates disclosure when ownership crosses specific thresholds, fitting the definition of MRQ better than DIRS (which is usually for individual director trades, though sometimes related). Given the focus on crossing ownership thresholds (franchissements de seuils), MRQ is the most appropriate classification.
2023-07-04 French
LE MARCHÉ DONNE RAISON À AKKADIAN PARTNERS ET SANCTIONNE LA FUSION ENTRE ERYTECH ET PHERECYDES
Legal Proceedings Report Classification · 1% confidence The document is a press release dated July 4, 2023, issued by Akkadian Partners concerning the merger between ERYTECH and PHONECYDES (resulting in Phaxiam Therapeutics). The core content details ongoing and planned legal proceedings (assignations, requests for expert opinions, potential criminal citations) against the management and shareholders involved in the merger, alleging fraud, improper voting procedures, and seeking compensation for shareholder losses. This content strongly aligns with reporting on significant lawsuits and regulatory actions involving the company, which falls under the 'Legal Proceedings Report' category. It is not a formal regulatory filing like a 10-K, an earnings release, or a general announcement of a report (RPA/RNS), but rather a detailed statement about litigation strategy.
2023-07-04 French
Franchissement de seuils
Major Shareholding Notification Classification · 1% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to a declaration of crossing ownership thresholds under French commercial code. This type of filing specifically reports changes in significant share ownership by an entity or individual, often crossing thresholds like 5%, 10%, etc. Reviewing the definitions, the category 'Major Shareholding Notification' (Code: MRQ) best fits this description, as it covers 'Notification of changes in significant share ownership levels (crossing thresholds)'. The document explicitly states that Tikehau Investment Management crossed the 5% threshold of capital and voting rights.
2023-07-03 French
Phaxiam Therapeutics annonce son nouveau code mnémonique sur Euronext et Nasdaq : PHXM
Regulatory Filings Classification · 1% confidence The document is a short press release announcing a corporate action: the change of the stock ticker symbol (mnémonique) from ERYP to PHXM following a merger. This is a material event announcement concerning the company's listing details. It is not a full financial report (10-K, IR, ER), a management change (MANG), or a dividend notice (DIV). Since it is a specific regulatory/market event announcement that doesn't fit the other specific categories like Capital Change (SHA) or Delisting (DLST), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous official announcements, or potentially a general announcement related to capital structure/listing, but RNS is the most appropriate general regulatory announcement code here.
2023-06-28 French
Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
Delisting Announcement Classification · 1% confidence The document is a short press release announcing a corporate action: a change in the company's mnemonic code (ticker symbol) from ERYP to PHXM following a merger. This type of announcement, which details a change in listing identifier or structure, does not fit neatly into standard financial reporting categories like 10-K, ER, or IR. It is a specific corporate event announcement. Since it is not a director's dealing (DIRS), dividend notice (DIV), capital change (SHA), or delisting (DLST), the most appropriate general category for a specific, non-standard regulatory or corporate update that doesn't fit elsewhere is 'Regulatory Filings' (RNS), as it is an official notification to the market regarding its listing details.
2023-06-28 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 26 juin 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 26 juin 2023" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of June 26, 2023). It explicitly references Article 223-16 of the General Regulation of the Autorité des Marchés Financiers (AMF). The content is a table detailing the evolution of the total number of shares and voting rights over several months, culminating in the current date. This type of mandatory monthly disclosure regarding the total share capital and voting rights structure is a specific regulatory filing requirement, often related to capital changes or major shareholdings, but the core focus here is the official count of shares and voting rights. This fits best under the category for notifications regarding changes in significant share ownership levels or capital structure updates, but given the specific nature of reporting total voting rights monthly, it is most closely aligned with regulatory reporting on share capital structure. Since there isn't a perfect fit for 'Monthly Voting Rights Disclosure', we must evaluate the closest options: 'SHA' (Share Issue/Capital Change) or 'MRQ' (Major Shareholding Notification). Because this is a routine, mandated disclosure of the total capital base, it is a fundamental regulatory filing. In many contexts, this specific type of filing (total voting rights disclosure) is often grouped with capital structure changes or major shareholding notifications. Given the data provided (total shares and voting rights), it is a direct report on the capital structure. 'SHA' covers share issues/capital changes, and while this isn't an announcement of a *change*, it is a report *on* the capital structure. 'MRQ' covers changes in *significant* ownership thresholds. Since this document reports the absolute total, it is a fundamental capital structure report. However, looking at the provided definitions, 'SHA' (Share Issue/Capital Change) is the closest category related to the composition of the share capital itself, even if it's a periodic update rather than a specific issuance announcement. Alternatively, if this is considered a general regulatory update not fitting elsewhere, 'RNS' would apply. Given the highly specific nature of the data (voting rights count), and the fact that it is a direct report rather than an announcement of a report (Rule 2), I will classify it as a report detailing the capital structure. Since the document reports the total number of shares and voting rights, which is a key component of capital structure reporting, 'SHA' is the most appropriate fit among the specific options, although 'RNS' is a possibility if it's deemed too routine for 'SHA'. I will lean towards 'SHA' as it directly concerns the share capital composition.
2023-06-27 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.